Lev News
Most Popular Lev Story
ViroPharma to buy Lev for $442M
ViroPharma has forged a deal to buy Lev Pharmaceuticals - a developer focused on developing inflammatory therapies -- for $442 million. The deal provides ViroPharma with Lev's Cinryze program, a... Read more...
Latest Headlines
- July 15, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
